Literature DB >> 20554627

Replication of CLU, CR1, and PICALM associations with alzheimer disease.

Minerva M Carrasquillo1, Olivia Belbin, Talisha A Hunter, Li Ma, Gina D Bisceglio, Fanggeng Zou, Julia E Crook, V Shane Pankratz, Dennis W Dickson, Neill R Graff-Radford, Ronald C Petersen, Kevin Morgan, Steven G Younkin.   

Abstract

OBJECTIVE: To test for replication of the association between variants in the CLU, CR1, and PICALM genes with Alzheimer disease.
DESIGN: Follow-up case-control association study.
SETTING: The Mayo Clinics at Jacksonville, Florida, and Rochester, Minnesota. PARTICIPANTS: Community-based patients of European descent with late-onset Alzheimer disease (LOAD) and controls without dementia who were seen at the Mayo clinics, and autopsy-confirmed cases and controls whose pathology was evaluated at the Mayo Clinic in Jacksonville. Additional samples were obtained from the National Cell Repository for Alzheimer Disease (NCRAD). A total of 1829 LOAD cases and 2576 controls were analyzed.
INTERVENTIONS: The most significant single-nucleotide polymorphisms in CLU (rs11136000), CR1 (rs3818361), and PICALM (rs3851179) were tested for allelic association with LOAD. Main Outcome Measure Clinical or pathology-confirmed diagnosis of LOAD.
RESULTS: Odds ratios for CLU, CR1, and PICALM were 0.82, 1.15, and 0.80, respectively, comparable in direction and magnitude with those originally reported. P values were 8.6 x 10(-5), .014, and 1.3 x 10(-5), respectively; they remain significant even after Bonferroni correction for the 3 single-nucleotide polymorphisms tested.
CONCLUSION: These results show near-perfect replication and provide the first additional evidence that CLU, CR1, and PICALM are associated with the risk of LOAD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20554627      PMCID: PMC2919638          DOI: 10.1001/archneurol.2010.147

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  22 in total

1.  Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers.

Authors:  B V Zlokovic; C L Martel; E Matsubara; J G McComb; G Zheng; R T McCluskey; B Frangione; J Ghiso
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

2.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

Authors:  E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance
Journal:  Science       Date:  1993-08-13       Impact factor: 47.728

3.  Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid beta.

Authors:  B V Zlokovic; C L Martel; J B Mackic; E Matsubara; T Wisniewski; J G McComb; B Frangione; J Ghiso
Journal:  Biochem Biophys Res Commun       Date:  1994-12-15       Impact factor: 3.575

4.  The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family.

Authors:  M H Dreyling; J A Martinez-Climent; M Zheng; J Mao; J D Rowley; S K Bohlander
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

5.  The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex.

Authors:  J Ghiso; E Matsubara; A Koudinov; N H Choi-Miura; M Tomita; T Wisniewski; B Frangione
Journal:  Biochem J       Date:  1993-07-01       Impact factor: 3.857

6.  Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease.

Authors:  Ronald B DeMattos; Mark A O'dell; Maia Parsadanian; Jennie W Taylor; Judith A K Harmony; Kelly R Bales; Steven M Paul; Bruce J Aronow; David M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-26       Impact factor: 11.205

7.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

8.  Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.

Authors:  A M Saunders; W J Strittmatter; D Schmechel; P H George-Hyslop; M A Pericak-Vance; S H Joo; B L Rosi; J F Gusella; D R Crapper-MacLachlan; M J Alberts
Journal:  Neurology       Date:  1993-08       Impact factor: 9.910

9.  Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid.

Authors:  A Golabek; M A Marques; M Lalowski; T Wisniewski
Journal:  Neurosci Lett       Date:  1995-05-19       Impact factor: 3.046

Review 10.  Genome-wide association studies in Alzheimer's disease.

Authors:  Lars Bertram; Rudolph E Tanzi
Journal:  Hum Mol Genet       Date:  2009-10-15       Impact factor: 6.150

View more
  105 in total

1.  Association studies of 19 candidate SNPs with sporadic Alzheimer's disease in the North Chinese Han population.

Authors:  Quan Yuan; Changbiao Chu; Jianping Jia
Journal:  Neurol Sci       Date:  2011-12-14       Impact factor: 3.307

Review 2.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2011-11-02       Impact factor: 21.566

3.  Hippocampal function in healthy carriers of the CLU Alzheimer's disease risk variant.

Authors:  Susanne Erk; Andreas Meyer-Lindenberg; Carola Opitz von Boberfeld; Christine Esslinger; Knut Schnell; Peter Kirsch; Manuel Mattheisen; Thomas W Mühleisen; Sven Cichon; Stephanie H Witt; Marcella Rietschel; Markus M Nöthen; Henrik Walter
Journal:  J Neurosci       Date:  2011-12-07       Impact factor: 6.167

4.  Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer's Disease.

Authors:  Davide Seripa; Francesco Panza; Giulia Paroni; Grazia D'Onofrio; Paola Bisceglia; Carolina Gravina; Maria Urbano; Madia Lozupone; Vincenzo Solfrizzi; Alessandra Bizzarro; Virginia Boccardi; Chiara Piccininni; Antonio Daniele; Giancarlo Logroscino; Patrizia Mecocci; Carlo Masullo; Antonio Greco
Journal:  Mol Neurobiol       Date:  2017-06-19       Impact factor: 5.590

Review 5.  The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy.

Authors:  Jin-Tai Yu; Lan Tan
Journal:  Mol Neurobiol       Date:  2012-01-25       Impact factor: 5.590

6.  Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis.

Authors:  Qingli Xiao; So-Chon Gil; Ping Yan; Yan Wang; Sharon Han; Ernie Gonzales; Ronaldo Perez; John R Cirrito; Jin-Moo Lee
Journal:  J Biol Chem       Date:  2012-04-26       Impact factor: 5.157

7.  Correlation of PICALM polymorphism rs3851179 with Alzheimer's disease among Caucasian and Chinese populations: a meta-analysis and systematic review.

Authors:  Bin Zhu; Li-Xia Li; Lei Zhang; Shu Yang; Yue Tian; Shan-Shan Guo; Wei Zhang; Zhi-Gang Zhao
Journal:  Metab Brain Dis       Date:  2018-07-23       Impact factor: 3.584

8.  Association between CLU gene rs11136000 polymorphism and Alzheimer's disease: an updated meta-analysis.

Authors:  Ruixia Zhu; Xu Liu; Zhiyi He
Journal:  Neurol Sci       Date:  2018-02-02       Impact factor: 3.307

9.  Combined effects of Alzheimer risk variants in the CLU and ApoE genes on ventricular expansion patterns in the elderly.

Authors:  Florence F Roussotte; Boris A Gutman; Sarah K Madsen; John B Colby; Paul M Thompson
Journal:  J Neurosci       Date:  2014-05-07       Impact factor: 6.167

Review 10.  Genomic variants, genes, and pathways of Alzheimer's disease: An overview.

Authors:  Adam C Naj; Gerard D Schellenberg
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-01       Impact factor: 3.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.